The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to comment on your Request for Information (RFI) on Medicare, CMS-4203-NC, published in the Federal Register on August 1, 2022. We applaud the agency’s effort to continue to improve and strengthen Medicare Advantage (MA) and ensure alignment with the Vision for Medicare and the CMS Strategic Pillars, released in April, that prioritize health equity to inure to the benefit of MA beneficiaries.